HUP0105230A2 - Specifikus hibrid promóterek alkalmazása szöveti kifejeződés szabályozására - Google Patents

Specifikus hibrid promóterek alkalmazása szöveti kifejeződés szabályozására

Info

Publication number
HUP0105230A2
HUP0105230A2 HU0105230A HUP0105230A HUP0105230A2 HU P0105230 A2 HUP0105230 A2 HU P0105230A2 HU 0105230 A HU0105230 A HU 0105230A HU P0105230 A HUP0105230 A HU P0105230A HU P0105230 A2 HUP0105230 A2 HU P0105230A2
Authority
HU
Hungary
Prior art keywords
hybrid promoters
tissue expression
specific hybrid
promoter
controlling tissue
Prior art date
Application number
HU0105230A
Other languages
English (en)
Inventor
Didier Branellec
Raphaël Darteil
Abderrahim Mahfoudi
Daniel Scherman
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9812000A external-priority patent/FR2783839B1/fr
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of HUP0105230A2 publication Critical patent/HUP0105230A2/hu
Publication of HUP0105230A3 publication Critical patent/HUP0105230A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A tal lm ny t rgy t egy olyan hibrid promóter képezi, amely mag bafoglalja - egy erős és ubikvista promóter/enhanszer enhanszer régiójnak egy részét vagy egészét, és - egy simaizom sejtekben specifikusexpressziót lehetővé tévő promóter régiót, valamint a tal lm ny t rgyae promótert tartalmazó b rmely vektor vagy sejt és azok alkalmaz sa. Ó
HU0105230A 1998-09-25 1999-09-23 Use of specific hybrid promoters for controlling tissue expression HUP0105230A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9812000A FR2783839B1 (fr) 1998-09-25 1998-09-25 Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire
US12329899P 1999-03-04 1999-03-04
PCT/FR1999/002265 WO2000018908A1 (fr) 1998-09-25 1999-09-23 Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire

Publications (2)

Publication Number Publication Date
HUP0105230A2 true HUP0105230A2 (hu) 2002-04-29
HUP0105230A3 HUP0105230A3 (en) 2003-10-28

Family

ID=26234566

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0105230A HUP0105230A3 (en) 1998-09-25 1999-09-23 Use of specific hybrid promoters for controlling tissue expression

Country Status (9)

Country Link
EP (1) EP1115857A1 (hu)
JP (1) JP2002525109A (hu)
KR (1) KR20010075338A (hu)
CN (1) CN1326506A (hu)
AU (1) AU775717B2 (hu)
CA (1) CA2343922A1 (hu)
HU (1) HUP0105230A3 (hu)
IL (1) IL142107A0 (hu)
WO (1) WO2000018908A1 (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7061401A (en) 2000-07-05 2002-01-14 Transgene Sa Chimeric promoters for controlling expression in smooth muscle cells
EP1310561A1 (en) * 2001-11-09 2003-05-14 Transgene S.A. Chimeric promoters for controlling expression in skeletal muscle cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266490A (en) * 1991-03-28 1993-11-30 Regeneron Pharmaceuticals, Inc. Mammalian expression vector
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
DE69534166T2 (de) * 1994-10-28 2006-03-09 Trustees Of The University Of Pennsylvania Rekombinanter adenovirus und methoden zu dessen verwendung
WO1998024922A1 (en) * 1996-12-02 1998-06-11 Valentis, Inc. Insulin-like growth factor i (igf-i) expression system and methods of use

Also Published As

Publication number Publication date
AU775717B2 (en) 2004-08-12
KR20010075338A (ko) 2001-08-09
CN1326506A (zh) 2001-12-12
HUP0105230A3 (en) 2003-10-28
JP2002525109A (ja) 2002-08-13
IL142107A0 (en) 2002-03-10
EP1115857A1 (fr) 2001-07-18
CA2343922A1 (fr) 2000-04-06
WO2000018908A1 (fr) 2000-04-06
AU5632499A (en) 2000-04-17

Similar Documents

Publication Publication Date Title
AU6613896A (en) Chemical compounds
AU4841700A (en) Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
BG102577A (en) New 5-amino-3-cyano-4-ethylsulphanyl-1-phenyl pyrazols and their use as pesticides
AU3264489A (en) 2-substituted-4-substituted-1,3-dioxalanes, synthesis and use thereof
MXPA04005266A (es) Inmunocitocinas con selectividad modulada.
AU5475096A (en) Mediators suitable for the electrochemical regeneration of NADH, NADPH or analogs thereof
YU19499A (sh) Benzonaftiridini kao bronhijalni terapeutici
AU6576898A (en) Fungicidal trifluorophenyl-triazolopyrimidines
AU1824600A (en) Low oxygen culturing of cells
AU9338598A (en) Recombinant vector containing infectious, viral genome sequences greater than 100 kb, method for producing same and use for the mutagenesis of the viral sequences
AU3378897A (en) Methods for generating side information in the presence of time-selective fading
MXPA03002911A (es) Compuestos quimicos.
EP1180024A4 (en) Z-STYRYL SULPHONES AS AN ANTI-CANCER
NO960645D0 (no) Kraftmaskin drevet av gass, spesielt hydrogen
AU2001281781A1 (en) Synthetic gagpol genes and their uses
IL129324A0 (en) Use of an H<+>, K<+>-ATPase inhibitor in the treatment of nasal polyps
IL90334A0 (en) Genetic transformation of b.thuringiensis,vectors used therefor,host cells transformed by the vectors and use of said cells as insecticides
DE69722031D1 (en) 4- (thien-3-yl)methyl] imidazolderivate mit alpha2-adrenoceptor agonistischer aktivität
HUP0105230A2 (hu) Specifikus hibrid promóterek alkalmazása szöveti kifejeződés szabályozására
MX9801496A (es) Uso de compuestos de aminoadamantano como inmunorreguladores.
PL311279A1 (en) Herbicidal substituted 1-phenyl or 1-pyridinyl benzotriazoles
DK1204659T3 (da) Serotonerge benzofuraner
IL142596A0 (en) Baculovirus expression system
TR199701202T1 (xx) Yeni hidroksimik asit t�revleri.
AU3126293A (en) Metal-air storage battery, rechargeable by addition of hydrogen

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees